Breast Cancer Research | |
Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy | |
Mattias Bergqvist1  Manuel Rodrigues2  Paul Cottu2  Florence Lerebours3  Marie-Laure Tanguy3  Anne Bethune3  Nicolas Kiavue3  Etienne Brain3  Delphine Loirat3  Anne Donnadieu3  Dan Rosenblum3  François-Clément Bidard4  Luc Cabel4  Jean-Yves Pierga5  | |
[1] Biovica, Uppsala, Sweden;Circulating Tumor Biomarkers Laboratory, SIRIC2 Institut Curie, Paris, France;Department of Medical Oncology, Institut Curie, Saint-Cloud, 92210, Paris, France;Department of Medical Oncology, Institut Curie, Saint-Cloud, 92210, Paris, France;Circulating Tumor Biomarkers Laboratory, SIRIC2 Institut Curie, Paris, France;UVSQ, Université Paris-Saclay, Saint-Cloud, Paris, France;Department of Medical Oncology, Institut Curie, Saint-Cloud, 92210, Paris, France;Circulating Tumor Biomarkers Laboratory, SIRIC2 Institut Curie, Paris, France;Université de Paris, Paris, France; | |
关键词: Metastatic breast cancer; CDK4/6 inhibitor; Palbociclib; Thymidine kinase 1; Biomarker; | |
DOI : 10.1186/s13058-020-01334-2 | |
来源: Springer | |
【 摘 要 】
PurposePrevious cohort studies have reported plasma TK1 activity (pTKa) as a potential prognostic biomarker in estrogen receptor-positive (ER+) HER2-negative (HER2−) metastatic breast cancer (MBC). In this prospective study, we report here the prognostic impact of pTKa in ER+/HER2− MBC patients treated with endocrine therapy and CDK4/6 inhibitor.Experimental designPatients were included into the prospective, ethics committee-approved ALCINA study (NCT02866149). Eligibility criteria were patients with ER+/HER2− MBC treated at Institut Curie with endocrine therapy and palbociclib. Plasma samples were obtained at baseline and after 4 weeks of treatment. pTKa was quantified by the DiviTum® assay (Biovica, Sweden).ResultsFrom May 2016 to August 2018, 103 patients treated with endocrine therapy and palbociclib were included. Patients had received a median of two prior systemic therapies for MBC (range 0–14). Median follow-up was 13.8 months (range 6–31), with median PFS and OS of 9.6 months (95%CI [7.0–11.3]) and 28 months (95%CI [23–not reached]), respectively. Median baseline pTKa was 292 Du/L (range 20–27,312 Du/L, IQR [89–853]). After adjusting for other prognostic factors, baseline pTKa remained an independent prognostic factor for both PFS (HR = 1.3 95%CI [1.1–1.4], p = 0.0005) and OS (HR = 1.3 95%CI [1.2–1.6], p < 0.0001), and 4-week pTKa was associated with OS (HR = 1.6 95%CI [1.3–2], p < 0.0001). That survival prediction was significantly improved by the addition of baseline pTKa to clinicopathological characteristics. Adding pTKa changes at 4 weeks to baseline pTKa did not further increase survival prediction.ConclusionThis study demonstrates the clinical validity of pTKa as a new circulating prognostic marker in ER+/HER2− MBC patients treated with endocrine therapy and palbociclib.
【 授权许可】
CC BY
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202104243085086ZK.pdf | 1296KB | download |